Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
09/02/2021 - 07:45 AM
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will participate in the Morgan Stanley 19th Annual Global Healthcare Conference to be held virtually September 9-15, 2021.
Details on the presentation and Q&A can be found below:
Date: Friday, September 10, 2021 Time: 2:00 p.m. Eastern
A live webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com . A webcast replay will be available for at least 30 days.
About Adagene
For more information, please visit: https://investor.adagene.com .
Internal Contact :ir@adagene.com
External Contact: bmackle@lifesciadvisors.com
ADAG Rankings
#384 Ranked by Stock Gains
ADAG Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
China (Mainland)
City
Suzhou
About ADAG
adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
